Italian drugmaker Alfasigma has entered into an exclusive licensing agreement with USA-based cardiopulmonary diseases focused company PhaseBio Pharmaceuticals (Nasdaq: PHAS) for the commercialization of bentracimab.
The agreement covers the countries of the European Union and the European Economic Area, as well as the UK, Russia, Ukraine and other countries of the Commonwealth of Independent States (CIS).
Bentracimab is a new human monoclonal antibody (MAb) fragment which in previous clinical studies has shown an immediate and prolonged reversal of the antiplatelet effects of Brilinta/Brilique (ticagrelor), which is marketed by Anglo-Swedish pharma major AstraZeneca (LSE: AZN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze